| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/29/2005 | EP1548008A1 Compound having tgf-beta inhibitory activity and medicinal composition containing the same |
| 06/29/2005 | EP1547615A1 Remedy |
| 06/29/2005 | EP1547603A2 Compositions and methods for use in targeting vascular destruction |
| 06/29/2005 | EP1547596A1 Medicinal composition and method for treating malignant tumor and utilization thereof |
| 06/29/2005 | EP1547588A1 Soft capsule preparation |
| 06/29/2005 | EP1546731A2 Method for treating or preventing metastasis of colorectal cancers |
| 06/29/2005 | EP1546730A2 Method for treating or preventing metastasis of colorectal cancers |
| 06/29/2005 | EP1546704A2 PAKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE |
| 06/29/2005 | EP1546703A2 RORs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| 06/29/2005 | EP1546375A2 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 06/29/2005 | EP1546369A2 Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| 06/29/2005 | EP1546361A1 Auto-stimulating cells and method for making and using the same |
| 06/29/2005 | EP1546206A1 Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes |
| 06/29/2005 | EP1546205A1 Methods for regulating cancer |
| 06/29/2005 | EP1546203A2 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| 06/29/2005 | EP1546196A1 Marker for cancer |
| 06/29/2005 | EP1546194A2 Therapeutic uspa1-derived peptides |
| 06/29/2005 | EP1546188A2 P53 binding t cell receptor molecules and uses thereof |
| 06/29/2005 | EP1546182A2 Compositions and methods for the diagnosis and treatment of tumor |
| 06/29/2005 | EP1546173A2 Methods of down regulating target gene expression in vivo by introduction of interfering rna |
| 06/29/2005 | EP1546156A1 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors |
| 06/29/2005 | EP1546152A1 Epothilone derivatives |
| 06/29/2005 | EP1546150A1 Biologically active compounds |
| 06/29/2005 | EP1546138A2 Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these |
| 06/29/2005 | EP1546137A1 Benzimidazol-1-yl-thiophene compounds for the treatment of cancer |
| 06/29/2005 | EP1546136A1 Benzopyran derivatives substituted with secondary amines including imidazole, their preparation and pharmaceutical compositions containing them |
| 06/29/2005 | EP1546127A1 Novel pyrimidineamide derivatives and the use thereof |
| 06/29/2005 | EP1546121A1 Substituted triazine kinase inhibitors |
| 06/29/2005 | EP1546117A2 Protein kinase inhibitors and uses thereof |
| 06/29/2005 | EP1546112A2 Imidazolopyridines and methods of making and using the same |
| 06/29/2005 | EP1546110A2 Compounds active in sphingosine 1-phosphate signaling |
| 06/29/2005 | EP1546087A1 3-amino-2-hrydroxyalkanoic acids and their prodrugs |
| 06/29/2005 | EP1546085A2 Lipophilic diesters of chelating agent for inhibition of enzyme activity |
| 06/29/2005 | EP1545710A2 Therapeutic use |
| 06/29/2005 | EP1545709A1 Neoadjuvant treatment of breast cancer |
| 06/29/2005 | EP1545616A1 Use of protein tyrosine phosphatase inhibitors for prevention and/or treatment of cancer |
| 06/29/2005 | EP1545614A2 Treatment of pathologies which escape the immune response, using optimised antibodies |
| 06/29/2005 | EP1545613A2 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| 06/29/2005 | EP1545592A1 Combination treatment of cancer using a cancer vaccine and a chemotherapeutic drug |
| 06/29/2005 | EP1545589A1 A method of modulating endothelial cell activity |
| 06/29/2005 | EP1545572A2 Conjugates activated by cell surface proteases and therapeutic uses thereof |
| 06/29/2005 | EP1545561A2 Compositions for treatment of prostate and other cancers |
| 06/29/2005 | EP1545556A2 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer |
| 06/29/2005 | EP1545553A1 Use of alkyl phosphocholines in combination with antitumor medicaments |
| 06/29/2005 | EP1545544A2 Combinations of drugs for the treatment of neoplasms |
| 06/29/2005 | EP1545533A1 Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 06/29/2005 | EP1545529A2 Novel tyrosine kinase inhibitors |
| 06/29/2005 | EP1545527A1 Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor |
| 06/29/2005 | EP1545523A1 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS |
| 06/29/2005 | EP1545519A1 Combination therapy for hyperproliferative diseases |
| 06/29/2005 | EP1545512A1 Methods for using gold (iii) complexes as anti-tumor and anti-hiv agents |
| 06/29/2005 | EP1545507A2 Activated checkpoint therapy and methods of use thereof |
| 06/29/2005 | EP1545500A1 Paclitaxel composition for the intravesical treatment of bladder tumor and preparation method thereof |
| 06/29/2005 | EP1545499A1 Composition for solubilization of paclitaxel and preparation method thereof |
| 06/29/2005 | EP1545498A2 Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same |
| 06/29/2005 | EP1545495A1 P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient |
| 06/29/2005 | EP1545482A1 Novel nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same |
| 06/29/2005 | EP1545481A1 Combination chemotherapy compositions and methods |
| 06/29/2005 | EP1545458A2 Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
| 06/29/2005 | EP1545204A2 Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| 06/29/2005 | EP1315727B1 7-oxo pyridopyrimidines |
| 06/29/2005 | EP1309672B1 Method of producing infectious reovirus |
| 06/29/2005 | EP1272507B1 Integrin binding peptide derivatives |
| 06/29/2005 | EP1184037B1 Use of 1,4-benzothiazepine derivatives as drugs overcoming carcinostatic tolerance |
| 06/29/2005 | EP1021186B1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha |
| 06/29/2005 | CN1633499A Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAs encoding the same |
| 06/29/2005 | CN1633440A Derivatives of branched-chain lipophilic molecules and uses thereof |
| 06/29/2005 | CN1633437A Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic |
| 06/29/2005 | CN1633436A Pyrrolopyrimidine derivatives |
| 06/29/2005 | CN1633433A N-aroyl cyclic amines |
| 06/29/2005 | CN1633431A 喹唑啉衍生物类激酶抑制剂 Quinazoline derivatives kinase inhibitors |
| 06/29/2005 | CN1633420A Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors |
| 06/29/2005 | CN1633419A CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| 06/29/2005 | CN1633418A Arylalkane-sulfonamides having endothelin-antagonist activity |
| 06/29/2005 | CN1633416A Nicotinamide derivates useful as p38 inhibitors |
| 06/29/2005 | CN1633414A Chemical compounds |
| 06/29/2005 | CN1633411A Compounds for modulating cell proliferation |
| 06/29/2005 | CN1633309A Method of radio-labelling biomolecules |
| 06/29/2005 | CN1633303A Method of protecting living body from foreign factor and composition therefor |
| 06/29/2005 | CN1633301A Extracts from sophora, production method and purposes thereof |
| 06/29/2005 | CN1633299A Estrogen replacement therapy |
| 06/29/2005 | CN1633297A Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 06/29/2005 | CN1633296A Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 06/29/2005 | CN1633294A 2, 4, 5-trisubstituded thiazolyl derivatives and their antiinflammatory activity |
| 06/29/2005 | CN1633290A Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| 06/29/2005 | CN1633289A Hemiasterlin derivatives and uses thereof |
| 06/29/2005 | CN1633288A Use of genistein in the manufacture of a medicament for the treatment of osteoporosis and obesity, and compositions containing genistein in combination with vitamin d and k |
| 06/29/2005 | CN1633287A Biphenil derivatives and their use as antiandrogenic agents |
| 06/29/2005 | CN1633285A 组合物 The composition |
| 06/29/2005 | CN1633284A Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
| 06/29/2005 | CN1632119A Human LSB gene sequence, encoded polypeptide thereof, preparation method and use therefor |
| 06/29/2005 | CN1632116A Enhancement of virus-mediated DNA transfer |
| 06/29/2005 | CN1632109A Highly expressed recombinant gutted adenovirus containing human constant region whole antibody gene and its use |
| 06/29/2005 | CN1631899A Use of DLP in Pre-mRNA splicing and cell cycle control |
| 06/29/2005 | CN1631898A Mitochondria traffic protein molecule for human marrow stromal cell and sequence encoding same and use thereof |
| 06/29/2005 | CN1631431A Method for extracting ganoderma lucidum spore fat soluble active substance and its specified instrument for preparation |
| 06/29/2005 | CN1631419A Phacellanthus extractive, its preparation and medical application |
| 06/29/2005 | CN1631415A Composition for improving life quality of cancer patients |
| 06/29/2005 | CN1631409A Extractive originated from cedrela sinensis, its preparation process and usage |
| 06/29/2005 | CN1631384A Powder for treating cancer |